About the Authors
- Hannah Mary Grayton
-
Affiliation Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, De Crespigny Park, London, United Kingdom
- Markus Missler
-
Affiliation Institute of Anatomy and Molecular Neurobiology, Westfälische Wilhelms-University, Münster, Germany
- David Andrew Collier
-
Contributed equally to this work with: David Andrew Collier, Cathy Fernandes
Affiliation Discovery Neuroscience Research, Eli Lilly and Company Ltd, Erl Wood, Windlesham, Surrey, United Kingdom
- Cathy Fernandes
-
Contributed equally to this work with: David Andrew Collier, Cathy Fernandes
* E-mail: catherine.fernandes@kcl.ac.uk
Affiliation Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, De Crespigny Park, London, United Kingdom
Competing Interests
Regarding the financial disclosure, the authors confirm that David A. Collier is a full time employee of Eli Lilly and Company Ltd. (since April 2012), and a visiting professor at the Institute of Psychiatry. David A. Collier is also a stockholder of Eli Lilly and Company. Eli Lilly and company provided an unrestricted educational grant to contribute to the breeding costs of the NRXN1 mice used in the present study. The present study does not relate to any patents, intellectual property, products in development or marketed products by Eli Lilly and Company. Cathy Fernandes has received an honorarium from Eli Lilly and Company Ltd. as a seminar speaker. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: HG CF DAC. Performed the experiments: HG CF. Analyzed the data: HG CF. Contributed reagents/materials/analysis tools: MM DAC. Wrote the paper: HG CF MM DAC.